Susceptibility of 100 strains of Stenotrophomonas maltophilia to three beta-lactams and five beta-lactam-beta-lactamase inhibitor combinations.
One hundred clinical strains of Stenotrophomonas maltophilia were investigated for their susceptibility to ticarcillin, piperacillin, ceftazidime and five combinations with beta-lactamase inhibitors (clavulanic acid, tazocillin or sulbactam) at three concentrations; 26% of the strains were susceptible to ticarcillin, 23% to ceftazidime and 12% to piperacillin. Eighty-two percent of the strains were susceptible to ticarcillin/clavulanic acid. In most cases, no synergy was observed with tazobactam or sulbactam. For eight ticarcillin-susceptible strains, antagonism was observed between ticarcillin and clavulanic acid.
Lecso-Bornet
M
M
Department of Microbiology, X. Bichat-Claude Bernard University Hospital, Paris, France.
Bergogne-Bérézin
E
E
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D004338:Drug Combinations; D004357:Drug Synergism; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D014974:Xanthomonas / Q000187:drug effects*; D065093:beta-Lactamase Inhibitors; D047090:beta-Lactams
D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D004791:Enzyme Inhibitors; D065093:beta-Lactamase Inhibitors; D047090:beta-Lactams